After comparing multiple clinical phenotypes in individuals with different TSC1/TSC2 mutation types, we found no significant differences in CNS, cutaneous manifestations, cardiac rhabdomyoma, renal system disorders, or TAND (Table 3). This evidence concerns the gene TSC2 and cardiac rhabdomyoma.